SpringerLink
Log in

The Impacts of Gastroileostomy Rat Model on Glucagon-like Peptide-1: a Promising Model to Control Type 2 Diabetes Mellitus

  • Original Contributions
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Background

One of the new current treatment options for Diabetes Mellitus is about increasing glucagon-like peptide-1 (GLP-1) activity. GLP-1 with its incretin effect showed major role in glucose homeostasis. Gastroileostomy can increase GLP-1 secretion by rapid delivery of undigested food to the terminal ileum. We studied the early effects of a gastroileostomy on serum levels of GLP-1, glucose, and insulin in rats.

Methods

Gastroileostomies with side-to-side anastomosis were performed on 15 male New Zealand rats. Blood samples were obtained before and 1 week after the gastroileostomy.

Results

Our results showed that the rats lost a lot of weight from start (330 ± 15 g) to the end (240 ± 25 g) of the experiment (p = 0.048). The data analysis showed that the gastroileostomy surgery elevates the level of GLP-1in plasma significantly (89.1852 vs. 177.440 respectively; p < 0.001) and caused a significant decrease in plasma glucose as well (92.00 and 66.29 mg/dL respectively; p < 0.001). However, the insulin state elevated after the surgery significantly (8.03 vs. 9.89; p < 0.001).

Conclusion

In this study, we showed the effectiveness of gastroileostomy treatment to decrease body weight and plasma glucose with increased GLP-1 in rats. This small rat model suggests the potential of this surgery to treat type 2 diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.

  2. Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab. 2004;89(7):3469–73.

    Article  PubMed  CAS  Google Scholar 

  3. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;10:CD006423.

    Google Scholar 

  4. Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014;63(1):9–19.

    Article  PubMed  CAS  Google Scholar 

  5. Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011;2(2):101–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–4.

    Article  PubMed  CAS  Google Scholar 

  7. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270–6.

    Article  PubMed  CAS  Google Scholar 

  8. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609–13.

    Article  PubMed  CAS  Google Scholar 

  9. Stoffers DA, Desai BM, DeLeon DD, et al. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes. 2003;52(3):734–40.

    Article  PubMed  CAS  Google Scholar 

  10. Parkes DJC, Smith P, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res. 2001;53:260–7.

    Article  CAS  Google Scholar 

  11. Stearns AT, Balakrishnan A, Tavakkolizadeh A. Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport. Am J Physiol Gastrointest Liver Physiol. 2009;297(5):G950–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Johannessen H, Kodama Y, Zhao CM, et al. Eating behavior and glucagon-like peptide-1-producing cells in interposed ileum and pancreatic islets in rats subjected to ileal interposition associated with sleeve gastrectomy. Obes Surg. 2013;23(1):39–49.

    Article  PubMed  Google Scholar 

  13. De Robertis E, Zito Marinosci G, Romano GM, et al. The use of sugammadex for bariatric surgery: analysis of recovery time from neuromuscular blockade and possible economic impact. Clinicoecon Outcomes Res. 2016;8:317–22.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Murphy R, Evennett NJ, Clarke MG, et al. Sleeve gastrectomy versus Roux-en-Y gastric bypass for type 2 diabetes and morbid obesity: double-blind randomised clinical trial protocol. BMJ Open. 2016;6(7):e011416.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Keidar A, Hershkop KJ, Marko L, et al. Roux-en-Y gastric bypass vs sleeve gastrectomy for obese patients with type 2 diabetes: a randomised trial. Diabetologia. 2013;56(9):1914–8.

    Article  PubMed  Google Scholar 

  16. Mahdy T, Schou C. Efficacy of single anastomosis sleeve ileal (SASI) bypass for type-2 diabetic morbid obese patients: gastric bipartition, a novel metabolic surgery procedure: a retrospective cohort study. Int J Surg. 2016;34:28–34.

    Article  PubMed  CAS  Google Scholar 

  17. Salama TMS, Sabry K, El Ghamrini Y. Single anastomosis sleeve ileal bypass: new step in the evolution of bariatric surgeries. J Investig Surg. 2017;30(5):291–6.

    Article  Google Scholar 

  18. Campos J, Ramos A, Szego T, et al. The role of metabolic surgery for patients with obesity grade I and clinically uncontrolled type 2 diabetes. Arq Bras Cir Dig. 2016;29:102–6.

    Article  PubMed Central  Google Scholar 

  19. Rizvi AA. The evolving role of bariatric surgery in patients with type 1 diabetes and obesity. Integr Obes Diabetes. 2016;2(2):195–9.

    PubMed  PubMed Central  Google Scholar 

  20. Vetter ML, Cardillo S, Rickels MR, et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009;150(2):94–103.

    Article  PubMed  Google Scholar 

  21. Ashrafian H, le Roux CW. Metabolic surgery and gut hormones—a review of bariatric entero-humoral modulation. Physiol Behav. 2009;97(5):620–31.

    Article  PubMed  CAS  Google Scholar 

  22. Jurowich CF, Otto C, Rikkala PR, et al. Ileal interposition in rats with experimental type 2 like diabetes improves glycemic control independently of glucose absorption. J Diabetes Res. 2015;2015:490365.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Nausheen S, Shah IH, Pezeshki A, et al. Effects of sleeve gastrectomy and ileal transposition, alone and in combination, on food intake, body weight, gut hormones, and glucose metabolism in rats. Am J Physiol Endocrinol Metab. 2013;305(4):E507–18.

    Article  PubMed  CAS  Google Scholar 

  24. Zhang H, Li J, Li Z, et al. Increased GLP-1 response after gavage-administration of glucose in UCP2-deficient mice. Horm Metab Res. 2012;44(2):86–90.

    Article  PubMed  CAS  Google Scholar 

  25. Imeryuz N, Yegen BC, Bozkurt A, et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Phys. 1997;273(4 Pt 1):G920–7.

    CAS  Google Scholar 

  26. Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317(3):1106–13.

    Article  PubMed  CAS  Google Scholar 

  27. Taqi E, Wallace LE, de Heuvel E, et al. The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J Pediatr Surg. 2010;45(5):987–95.

    Article  PubMed  Google Scholar 

  28. Patriti A, Aisa MC, Annetti C, et al. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery. 2007;142(1):74–85.

    Article  PubMed  Google Scholar 

  29. Li J, Lai D, Wu D. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy to treat morbid obesity-related comorbidities: a systematic review and meta-analysis. Obes Surg. 2016;26(2):429–42.

    Article  PubMed  Google Scholar 

  30. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Mahawar KK, Parikh C, Carr WR, et al. Primary banded Roux-en-Y gastric bypass: a systematic review. Obes Surg. 2014;24(10):1771–92.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors acknowledge Mr. Amirsalar Moazen Safaei and Mr. Aria Azarshahi for their help in proofreading this manuscript.

Author information

Authors and Affiliations

  1. Isfahan Minimally Invasive Surgery and Obesity (IMISO) Center, Department of Surgery, Isfahan University of Medical Sciences, Isfahan, Iran

    Behrouz Keleidari & Shahab Shahabi Shahmiri

  2. Department of Surgery, Isfahan University of Medical Sciences, Isfahan, Iran

    Rastin Mohammadi Mofrad

  3. Department of Pathology, Al Zahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

    Mohammad Hossein Sanei

  4. Department of Thoracic Surgery, Al Zahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

    Mohsen Kolahdouzan

  5. Student Research Committee, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

    Erfan Sheikhbahaei

Authors
  1. Behrouz Keleidari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rastin Mohammadi Mofrad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shahab Shahabi Shahmiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Hossein Sanei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohsen Kolahdouzan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erfan Sheikhbahaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shahab Shahabi Shahmiri.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding Resource

No fund received for this research.

Ethics Statements

This research commenced after fulfilling all of the ethical statements and receiving its approval from department of ethics in medical research. All procedures were conducted in agreement with the National Institutes of Health Guide for Care and Use of Laboratory Animals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keleidari, B., Mohammadi Mofrad, R., Shahabi Shahmiri, S. et al. The Impacts of Gastroileostomy Rat Model on Glucagon-like Peptide-1: a Promising Model to Control Type 2 Diabetes Mellitus. OBES SURG 28, 3246–3252 (2018). https://doi.org/10.1007/s11695-018-3312-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-018-3312-y

Keywords

Search

Navigation